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Abstract
MicroRNAs (miRNAs) are small endogenous regulatory molecules that modulate gene expression
post-transcriptionally. Although differential expression of miRNAs have been implicated in many dis-
eases (including cancers), the underlying mechanisms of action remain unclear. Because each miRNA
can target multiple genes, miRNAs may potentially have functional implications for the overall behavior
of entire pathways. Here we investigate the functional consequences of miRNA dysregulation through an
integrative analysis of miRNA and mRNA expression data using a novel approach that incorporates path-
way information a priori. By searching for miRNA–pathway associations that differ between healthy
and tumor tissue, we identify specific relationships at the systems–level which are disrupted in cancer.
Our approach is motivated by the hypothesis that if a miRNA and pathway are associated, then the ex-
pression of the miRNA and the collective behavior of the genes in a pathway will be correlated. As such,
we first obtain an expression–based summary of pathway activity using Isomap, a dimension reduction
method which can articulate nonlinear structure in high-dimensional data. We then search for miRNAs
that exhibit differential correlations with the pathway summary between phenotypes as a means of find-
ing aberrant miRNA–pathway coregulation in tumors. We apply our method to cancer data using gene
and miRNA expression datasets from The Cancer Genome Atlas (TCGA) and compare ∼105 miRNA–
pathway relationships between healthy and tumor samples from four tissues (breast, prostate, lung, and
liver). Many of the flagged pairs we identify have a biological basis for disruption in cancer.
1 Introduction
Cellular functions are carried out by coordinated regulation of genes on a pathway, which facilitate a series
of interactions among genes to produce behaviors as diverse as cell metabolism to cell signaling. At the post-
transcriptional level, microRNAs (miRNAs, miRs) modulate gene expression by binding to a 6-8 nucleotide
target motif of mRNA transcripts, preventing translation and/or inducing degradation of their target genes.
Due to the short binding motif, miRNA targeting is non-specific, such that a single miRNA may target mul-
tiple genes, and likewise, a single gene may be targeted by multiple miRNAs [1]. Currently, it is estimated
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Figure 1: An example of two genes cycling out of phase with one-another, with the amplitude of the oscilla-
tion governed by the expression of a miRNA. The relationship is apparent in the left panel, where the lower
values of the miRNA result in a smaller radius in the relationship between gene X and gene Y, yet neither
gene X nor gene Y are correlated with the miRNA (right panels, top and bottom).
that ∼103 known miRNAs regulate approximately a third of genes in the genome [2, 3, 4]. However, not
all miRNA–gene relationships are known; studies to predict miRNA targets using sequence matching have
had mixed success [5], and the functional consequences of miRNA dysregulation remains an area of active
research. It is now thought that the mutliplicity of targets enables miRNAs to exert a cumulative effect at the
systems level, by targeting several genes and influencing their downstream interactions. miRNAs have been
hypothesized to modulate pathways by regulating targets constituting those pathways [6, 7, 8, 9, 10]. Such
systems–level control may explain the association of aberrant miRNA regulation with multiple diseases,
including cancer [11, 12], endometriosis [13], inflammation [14], and several others.
High–throughput transcriptomics datasets now enable us to investigate the role of miRNAs in regulating
pathway activity by integratively analyzing miRNA and gene expression from the same samples. Such
analyses must address the challenges inherent to high–throughput data, including the fact that the number
of features typically exceeds the number of samples by orders of magnitude, the data are inherently noisy,
and many features may be irrelevant to the phenotype of interest. In addition, integrative analyses should
account for the multiplicity of interactions that collectively contribute to phenotypic differences. Approaches
for integrative miRNA–mRNA analysis generally fall into two categories [15]: (i) inferring interacting miR–
mRNA pairs from transcriptomic data (e.g., by searching for high correlations [16], using regularized linear
regression [17, 18], or mutual information [19]); and (ii) combining miRNA and mRNA expression data
to identify a signature in the combined feature space that predicts the phenotype of interest [20, 21] (e.g.,
using non-negative matrix factorization [22] or clustering [23] to find combinations of miRNAs and genes
that most strongly predict outcomes). A comprehensive review of integrative miRNA–mRNA analysis may
be found in [15].
Information about gene interaction networks obtained from pathway databases (such as KEGG [24] or
PID [25]) can be used to reduce dimensionality and improve interpretability by focusing on functionally
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related gene sets. To date, however, most miRNA–mRNA integrative analyses do not explicitly incorporate
this information a priori; instead, the interactions and signatures identified in the analysis are tested for
overlap with known pathways at the end to lend a systems–level interpretation of the gene–level findings [26,
27]. Because many pathway analysis approaches (including enrichment methods such as GSEA [28]) rely
on aggregating single–gene statistics rather than treating the pathway as a whole, they may miss crucial
multi–gene interactions, such as the loss of coordinated expression. For example, the relevance of a miRNA
that governs the relationship between two genes (such as the amplitude of the oscillation shown in Fig. 1)
can be missed when considering the target genes in isolation, since neither gene is independently associated
with the miRNA.
To overcome this limitation, several groups have proposed schemes to summarize gene expression ac-
cross the pathway to quantify the overall level of pathway ‘activity’ in each sample [29, 30]. These ap-
proaches apply dimension reduction techniques (such as Singular Value Decomposition [SVD] and Principal
Components Analysis [PCA]) to pre-defined gene sets, effectively yielding a single value that encapsulates
the coarse coexpression behavior of all the genes in the pathway. In the PLAGE method [29], SVD was used
to obtain a “pathway activity level” quantification based on the expression of genes in the pathway. A sim-
ilar approach using PCA was employed in the GPC-Score [30] method. A nonlinear dimension reduction
strategy for pathway summarization was considered in [31], which was shown to more faithfully summarize
complex coexpression patterns than linear methods. More recently, the COMPADRE package [32] presented
a framework for pathway summarization using a variety of dimension reduction techniques (including SVD,
PCA, ICA, non-negative matrix factorization, and non-linear Isomap). The resulting pathway–level quan-
tifications may then be tested for statistical associations with the phenotype, allowing the pathway to be
treated as a single functional unit.
Here we propose a method that identifies miRNAs that differentially regulate the overall activity of
pathways by using a pathway summarization technique capable of articulating nonlinear and multi-gene
effects. Motivated by the observation that nonlinear dimension reduction can yield more accurate results
when applied to gene expression data [33, 34, 31], our method uses Isomap [35], a nonlinear dimension
reduction (NLDR) method, to summarize pathway expression to yield a low-dimensional summary that we
call the Pathway Activity Summary (PAS). The PAS provides a faithful “snapshot” of the pathway, a coarse
measure of pathway expression in all samples. Our method then computes correlation coefficients between
PAS and miRNA expression to identify miRNAs whose expression is associated with the overall activity
of the pathway. By comparing class–conditional correlations in cases and controls, we identify miRNA–
pathway pairs that appear to have a differential relationship in cases and controls, elucidating the function
of the miRNA and its potential mechanistic role in the phenotype of interest.
The approach used here is similar in some respects to our GPC-score method [30], which reveals novel
regulatory relationships between genes and pathways. Using PCA for pathway summarization, GPC-score
was able to identify differentially regulated gene–pathway pairs and accurately detect the interaction of
genes with pathways that were not previously known to include them. The present work augments this prior
analysis method in two novel ways. First, by using the nonlinear Isomap instead of PCA, we obtain a more
faithful summary of pathway activity. Second, by applying the method to miRNA and mRNA data (rather
than simply mRNA data), we achieve an integrative analysis of these datasets that can provide insight into
the function of miRNAs. We apply this method to miRNA and mRNA expression profiles from four cancers
(breast, liver, lung, and prostate) using data from The Cancer Genome Atlas (TCGA) [36].
Previous analyses have integrated multiple omics platforms to identify specific mechanisms regulat-
ing gene expression. Several pipelines have taken into account sample-specific data from TCGA at the
transcriptomic, genomic, and epigenetic levels and have linked them with cell-generic data from other con-
sortiums [37, 38]. These studies have identified relationships between expression regulators and genes in
some cancer types. Recently, the TCGA Network surveyed miRNAs in the context of expression patterns
and clinical outcomes in ovarian cancer, and found widespread impact on gene expression and molecular
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heterogeneity [39]. Our method is also integrative, but novel in that it surveys miRNA regulation in the con-
text of gene expression from a pathway perspective. Importantly, because our approach uses both miRNA
and mRNA expression data, it avoids some of the pitfalls that were previously identified [40] with making
pathway–level inferences from miRNA data alone.
In this study, we apply our methodology to gene and miRNA expression datasets from The Cancer
Genome Atlas (TCGA) (http://cancergenome.nih.gov/), a freely accessible repository of high dimensional
genomic and expression data for several cancers. The datasets include both tumor and adjacent-normal tissue
samples across multiple experimental modalities. After identifying class-conditional correlation differences
for all possible miRNA–pathway pairs, we assess their significance through permutation testing. We report
miRNAs that appear to have pathway-wide effects whose relationships change with the development of
cancer, and report results for multiple distinct cancers.
2 Materials and Methods
In order to elucidate the functional role of miRNAs in cancer, we seek to identify miRNAs that appear
to influence the overall activity of a pathway, and whose effects on that pathway appear to differ between
healthy and tumor tissue. To do so, we first compute a pathway activity summary for each sample in
each pathway of interest using gene expression data. We then compute, class–conditionally, the correlation
between the pathway expression summary and each miRNA in cases and controls to quantify the miRNA–
pathway relationship in those tissues, and test whether tumor–normal differences in the miRNA–pathway
correlations are statistically significant. We detail the steps of this algorithm below; a summary may be
found in Table 1 and Figure 2.
2.1 Algorithm
To identify miRNAs whose effects across entire systems differ between two conditions, we compute the
association of miRNAs with pathways and compare associations between phenotypes by correlating miRNA
and pathway gene expression. Because a given pathway may comprise tens to hundreds of genes, we use
Isomap [35] to compute a one-dimensional summary of gene expression across the pathway, which we
call the Pathway Activity Summary (PAS). Here, each sample can be be thought of as a point in a high–
dimensional space whose coordinates correspond to the expression of the genes on that pathway. Because
the underlying biology places constraints on the expression of these genes with respect to one another, we
make the assumption that the samples lie on a low–dimensional manifold within the gene expression space.
Isomap attempts to learn this manifold, yielding a coordinate that articulates the variability amongst samples;
projecting the gene expression data from sample j onto this coordinate obtains the pathway activity score
PASj for sample j across the pathway of interest. (The approach is analogous to that of PCA; in contrast to
PCA, however, the Isomap coordinate need not be a linear transformation of the gene expression space.) By
obtaining PAS values for each sample, we can then compare pathway activity in cases and controls, and test
the association of pathway activity with other variables of interest.
Relationships between miRNA expression and pathway activity are then compared between phenotypes
as follows. The correlation between the PAS for a pathway and expression for a miRNA is computed class-
conditionally, i.e. separately for tumor and normal samples. We then compute the absolute difference of the
miRNA–pathway correlation in tumor and normal tissue:
∆ρ(miR,PAS) =
∣∣ρ(miR,PAS|T )− ρ(miR,PAS|N)∣∣ (1)
where ρ(x, y) is the Spearman rank correlation between x and y, chosen for its insensitivity to outliers, and
T and N indicate tumor and normal tissue, respectively. A large correlation difference ∆ρ between sample
4
Table 1: Procedure for assessing disrupted pathways regulated by miRNAs.
miRNA–pathway Algorithm
1. Subset gene expression data to the pathway genes, forming pathway expression matrix of l genes × N samples.
2. Apply Isomap to pathway matrix using all samples, obtaining for each sample a PAS value based on the first
Isomap coordinate (analogous to using the first principal component from PCA).
3. Compute the Spearman rank correlation between the miRNA and the PASin tumor samples, ρ
(
miR,PAS|T ).
4. Compute the Spearman rank correlation between the miRNA and the PASin normal samples, ρ
(
miR,PAS|N).
5. Compute absolute correlation difference between phenotypes as shown in Equation 1.
6. Repeat steps 3-5 using randomly permuted phenotype labels for 105 resamplings to compute the null distribution
of ∆ρ’s.
7. Compare the true miRNA–pathway ∆ρ to the permuted null distribution obtained in step 6 to assess statistical
significance of ∆ρ.
PAS1 PAS2 ! PASj( )Genes
Samples
Isomap
ρ |T =Cor miR,PAS |T( )
ρ | N =Cor miR,PAS | N( )
miR1 miR2 ! miRj( )
PAS1 PAS2 ! PASj( )
Δρ = ρ |T( )− ρ | N( )
a
b
c
miR1 miR2 ! miRj( )
PAS1 PAS2 ! PASj( )
N resamplings
Δρ
*	  
*	  
*	  *	  
*	  
*	  
null
Figure 2: Illustration of the algorithm for a particular miRNA–pathway pair. (a) Gene expression data is
first subsetted by the genes in a pathway and summarized by Isomap to produce the PAS, a one-dimensional
summary of pathway expression in all samples. (b) PAS and miRNA expression are subsetted by phenotype,
and miRNA–pathway correlations are computed for tumor and normal tissue. The difference between corre-
lations gives ∆ρ. (c) To assess ∆ρ significance, the ∆ρ null distribution is estimated by random permutation
of the class labels.
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Figure 3: Swiss roll dimension reduction using PCA and Isomap. The roll is colored from green to red along
the roll axis.
classes indicates apparent differential regulation of a pathway by a miRNA. Significance of the correlation
difference is assessed by a permutation test, wherein the tumor and normal labels are randomly reassigned
and Eq. 1 is recomputed to obtain a reference distribution for the miRNA–pathway pair. The steps for the
algorithm are listed in Table 1. Figure 2 illustrates the algorithm in visual form.
2.2 Implementation
Here we detail the implementation of the algorithm as applied to mRNA and miRNA data from TCGA.
Additional details are provided in the Supplementary Information.
2.2.1 Pathway summarization
The goal of pathway summarization is to reduce the dimensionality from that of l genes on the pathway to
a single value that encapsulates the pathway activity for each sample. To this end, we define the PAS as the
one-dimensional embedding of the pathway mRNA data using Isomap.
The choice to use Isomap for pathway summarization rather than SVD [29] or PCA [30] is motivated
by its ability to articulate non-linear geometries in the data. A toy example comparing Isomap to PCA is
shown in Figure 3. Here, the data lie on a two dimensional manifold that is coiled upon itself in 3-d space;
dimension reduction via Isomap articulates this surface, whereas PCA cannot.
For each pathway in the KEGG [24] database, mRNA expression data are subsetted to the genes as-
sociated with that pathway to produce pathway-specific matrices. A total of 223 pathways are included in
the analysis (after excluding six pathways with fewer than five genes). Expression levels for each gene are
scaled to have zero mean and unit variance, allowing features to be measured on the same scale and reducing
the disproportionate influence of any outlying samples. Isomap is then applied to the pathway gene expres-
sion data, and the projection of the sample on the first Isomap coordinate is used as a measure of the overall
activity of the pathway.
An example of the utility of Isomap for summarizing gene expression data is given in Figure 4, where
the 39-gene “Type I diabetes mellitus pathway” is summarized by PCA (left) and Isomap (right) for the
TCGA breast cancer and normal tissue samples. Because Type I diabetes mellitus has been associated with
an increased risk of breast cancer [41, 42] and several genes in the pathway are known tumor suppressors
and cytokines that are commonly perturbed in tumors, we expect that a low dimensional embedding of the
data should enable separation of the tumor and normal samples. However, we observe that this difference
is not articulated using PCA; in the left scatterplot matrix of Figure 4, the red and black points overlap.
By contrast, the Isomap embedding enables separation of the tumor and normal samples, suggesting that
there exists a (nonlinear) pattern of gene expression within the pathway that is associated with breast cancer.
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Figure 4: Comparison of gene expression dimension reduction using PCA (left) and Isomap (right) for
genes in the Type I diabetes mellitus pathway. Black circles represent TCGA breast cancer tumor tissue
and red triangles represent adjacent-normal. Plotted are the projections of the samples in the first four PCA
coordinates (left) and first two Isomap coordinates (right). The Isomap embedding enables separation of the
tumor and normal samples not achieved by PCA, suggesting that a non-linear pattern of gene expression
within the pathway distinguishes tumor and normal samples.
This example motivates the choice of nonlinear dimension reduction as a means of quantifying the overall
behavior of a pathway.
2.2.2 Isomap parameter choice
Isomap has one free parameter, k, which defines the k-nearest neighbors used in reconstructing the local
geometry [35]. Choosing the optimal value of k is an open question, and different values have the potential to
produce different embeddings. We devised a data–driven method for selecting k by employing a comparison
between the spectra of PCA and Isomap.
Isomap applies MDS [43] on a distance matrix that approximates geodesic distances, constructed by a
k-nearest neighbors search and computing shortest paths. This may be thought of as a localized form of
MDS (or, equivalently, PCA [43]), which classically uses distances between all pairs to articulate the global
geometry. Like PCA and MDS, Isomap also yields a spectrum of eigenvalues whose magnitude indicates
the proportion of variability in the data that is articulated by the corresponding coordinate.
We capitalize on this feature by comparing the spectra of PCA and ISOMAP for different values of
k. Spectral comparisons can help find embeddings most different from each other, and may reveal those
that articulate manifolds with nonlinear structures. In PCA, one chooses the number of components to be
retained such that the majority of the variance in the data is captured. A common visualization is the “scree
plot” in which the variance for each component (eigenvalues λ0 ≥ λ1,≥ · · · ≥ λn) is displayed; one looks
for an elbow in the spectrum indicating that additional components do not appreciably reduce the residual
variance. Mathematically, an elbow at the first component will have a large ratio between the first two
eigengaps (i.e., a large change between the first and second eigenvalues, followed by a much smaller change
between the second and third), which we call the spectral gap ratio (SGR), SGR = λ0−λ1λ1−λ2 .
We choose Isomap k such that it maximizes the SGR ratio between Isomap and PCA, SGRISOMAPSGRPCA ,
noting that when k = N − 1 (all data treated as nearest-neighbors), Isomap and PCA yield equivalent
spectra. The optimal k is guaranteed to yield SGRISOMAPSGRPCA ≥ 1; that is, it produces an embedding that
explains at least as much variance in the first component as PCA. By choosing k to maximize this ratio,
we obtain the greatest improvement by Isomap over PCA, which will occur when the data lie on a curved
manifold that cannot be articulated by PCA.
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Figure 5: Two-dimensional embedding of the Swiss roll using Isomap for different k values. The bottom
right plot shows the spectra using PCA (black dots), and for k = 3 (red), k = 6 (green), and k = 16 (blue)
using Isomap. Our “optimal” k’s spectra, k = 6, is most different than PCA’s spectra, as computed by the
SGR ratio defined in the methods section.
To illustrate our methodology, we apply Isomap to the Swiss roll dataset using different values of k
in Figure 5. The “optimal” k (k = 6) produces an embedding that reflects the low-dimensional intrinsic
geometry of the roll, the unraveled 2D surface. In comparison, a value is that is too small (k = 3) will be
sensitive to local distortions, whereas a value that is too large (k = 16) will produce an embedding that
poorly learns the intrinsic coordinates. The spectra for all three Isomap embeddings, in addition to the PCA
spectrum, are shown in the right-most plot in Figure 5. The green empty circles, corresponding to (k = 6),
have the largest SGRISOMAPSGRPCA , whereas other k’s have smaller SGR as shown by the red (k = 3) and blue
(k = 16) empty circles. The “optimal” k produces a PAS that captures the geodesic of the Swiss roll. We
applied this methodology to pathway data such that the PAS best represents the geometry of the data in the
high-dimensional space.
2.2.3 PAS correlation with miRNAs
Once the PAS is computed, correlations between each pathway’s PAS with each miRNA’s expression are
computed class-conditionally. miRNA–pathway correlation differences (∆ρ) are computed between tumor
and adjacent-normal tissue samples as shown in Equation 1. We emphasize that the PAS is computed
class-inclusively (both tumor and adjacent-normal tissue) so that different phenotypes are summarized in
context with each other. Thus, we can compare phenotypes on the same scale and quantify their gene
expression differences across the pathway. Afterwards, we restrict samples to each phenotype and compute
their correlation with miRNAs class-conditionally. This enables us to compare how the relationship between
a miRNA and a pathway differs in tumor and normal tissue.
The significance of each ∆ρ is assessed by permutation tests. Each miRNA–pathway pair’s ∆ρ null
distribution is estimated by randomly permuting class labels and recomputing ∆ρ for 105 resamplings.
Within each resampling, the same number of nominal tumor and adjacent-normal samples is preserved.
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Figure 6: Representative examples of significant miRNA–pathway pairs for all four cancers. miRNA–
pathway pairs with the largest ∆ρ are shown for each cancer (p<10−5). Tumor samples are represented by
red circles and adjacent-normal samples by blue triangles. LOESS curves are overlaid by tissue type (solid
line for tumor tissue, dotted line for adjacent-normal tissue) to visualize correlation differences. The number
of genes in the pathway which have been used in the computation of the PAS are shown in parenthesis.
Adjustment for the multiple hypotheses tested is also achieved through permutation [44].
3 Results
miRNAs with median expression above 0.001 (444 in breast, 455 in liver, 484 in lung, and 416 in prostate)
and pathways with greater than five genes (223 pathways) were considered. Each possible miRNA–pathway
pair (∼105 pairs) was analyzed for differential association between tumor and adjacent-normal tissue within
each organ (breast, prostate, lung, and liver) by computing its ∆ρ and assessing ∆ρ significance to identify
organ-specific relationships between miRNAs and pathways that appear to be strongly altered in tumors.
Multiple hypothesis correction was achieved through permutation [44].
We illustrate aberrant miRNA regulation of pathways in tumor tissue by showing sample miRNA vs.
PAS expression plots which have the most pronounced class-correlation differences (Figure 6). In the plots,
tumor samples exhibit distinct trends from adjacent-normal samples for the same miRNA and pathway in
the same organ.
In these particular cases, the PAS alone can distinguish phenotypes, as demonstrated by the difference
in the location of the tumor and normal samples along the x-axes. However, we emphasize that differential
9
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Figure 7: Example of a miRNA–pathway pair (miRNA ID: hsa-mir-193a, KEGG pathway ID: 04115) with
significant ∆ρ (∆ρ = −0.64, p<10−4) despite no differential expression in prostate cancer. Absence of
differential expression is visualized by a rug plot on the top and right. Our method is capable of articulating
significant miRNA–pathway coregulation differences regardless of differential expression across either the
pathway or miRNA.
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Table 2: Top breast cancer pairs sorted by the most pronounced ∆ρ (p<10−5). ρT and ρN are the within-
tissue Spearman’s rank correlation for tumor tissue and normal tissue, respectively. Size denotes the number
of genes in the pathway that have been used in the computation of the the PAS. Targets denotes the number
of predicted targets of the miRNA on those genes using TargetScan [48]. In parenthesis, the total number of
genes and targets of the miRNA on the pathway are shown.
miRNA KEGG ID KEGG name ∆ρ ρT ρN size targets
hsa-mir-146b 00330 Arginine and proline metabolism 1.15 0.44 -0.71 49(54) 1(1)
hsa-mir-146b 05110 Vibrio cholerae infection 1.12 0.44 -0.68 51(54) 0(0)
hsa-mir-146b 05217 Basal cell carcinoma 1.11 0.45 -0.66 53(55) 1(1)
hsa-mir-146b 05200 Pathways in cancer -1.10 -0.49 0.61 316(326) 10(10)
hsa-mir-135b 00980 Metabolism of xenobiotics by cytochrome P450 1.10 0.48 -0.63 49(71) 0(0)
hsa-mir-146b 05120 Epithelial cell signaling in Helicobacter pylori infection 1.10 0.47 -0.63 66(68) 0(0)
hsa-mir-135b 05217 Basal cell carcinoma 1.08 0.48 -0.60 53(55) 5(5)
hsa-mir-146b 00980 Metabolism of xenobiotics by cytochrome P450 1.08 0.46 -0.61 49(71) 0(0)
hsa-mir-99a 00590 Arachidonic acid metabolism 1.07 0.49 -0.58 48(59) 0(0)
hsa-mir-135b 00520 Amino sugar and nucleotide sugar metabolism 1.07 0.44 -0.63 47(48) 0(0)
hsa-mir-1307 00830 Retinol metabolism -1.07 -0.51 0.56 42(64) 0(0)
hsa-mir-1307 04976 Bile secretion -1.06 -0.61 0.45 56(71) 0(0)
hsa-mir-135b 00051 Fructose and mannose metabolism 1.06 0.44 -0.63 35(36) 1(1)
hsa-mir-135b 05120 Epithelial cell signaling in Helicobacter pylori infection 1.06 0.41 -0.65 66(68) 4(4)
hsa-mir-224 01040 Biosynthesis of unsaturated fatty acids 1.06 0.40 -0.65 19(21) 0(0)
expression within a pathway is unnecessary for achieving significance. Our method also detects aberrant
signaling even when no marginal differences can be detected. Figure 7 shows a sample miRNA vs. pathway
expression plot in prostate cancer with a significant correlation change despite a lack of differential expres-
sion across either the PAS or miRNA. Such a pair would not be detected using methods which rely on single
gene association statistics, or by looking at the pathway in isolation without the miRNA.
Importantly, other evidence from the literature supports the association of this miRNA–pathway pair.
The miRNA in Figure 7, hsa-mir-193a, is a tumor suppressor implicated in several cancers whose down-
regulation has been proposed as a biomarker of oncogenesis [45, 27, 46]. The p53 signaling pathway,
a tumor suppressing pathway which responds to cell stress, can activate cell cycle arrest, senescence, or
apoptosis. It is known as a prominent regulator which is commonly disrupted in cancer cells [47], and its
main tumor protein TP53 is the most mutated gene in cancer. In addition, the p53 pathway contains three
genes which are predicted to be targets of hsa-mir-193a (CCND1, SIAH1, and ZMAT3). This example
serves to illustrate the capabilities of the method to detect biologically meaningful relationships between
miRNA expression and pathway activity.
In the following sections, we list the top 15 pairs with the most pronounced ∆ρ for each cancer type.
The remaining pairs at the same level of significance are listed in the Supplementary Information. Many of
the flagged miRNAs and pathways have a biological basis for disruption in cancer.
3.1 Breast Cancer
Breast cancer pairs with large ∆ρ are shown in Table 2. miRNAs hsa-mir-146b and hsa-mir-135b each
regulate multiple pathways class-conditionally and have functional relevance to cancer in the literature.
Specifically, hsa-mir-146b is a known tumor suppressor [49, 50] that inhibits NF-kB induction of IL-6 to
prevent inflammation in breast cells, which chronically leads to oncogenesis. In breast cancer cells, however,
promoter methylation decreases hsa-mir-146b expression [51]. hsa-mir-135b has previously been associated
with several cancer types, including prostate, lung, and most prominently colon cancer. In colon cancer,
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upregulation of hsa-mir-135b promotes cancer progression, and activation of hsa-mir-135b is triggered by
oncogenic pathways [52]. The IL-1R1 pathway, which involves regulation of immune and inflammatory
responses, has recently been found to regulate hsa-mir-135b expression in smoke-induced inflammation in
lung cells [53].
It is notable that several pathways which are listed, including those differentially regulated by hsa-mir-
146b and hsa-mir-135b, are inflammatory. Infectious disease pathways, including Vibrio cholerae infection
and Epithelial cell signaling in Helicobacter pylori infection, activate proinflammatory responses including
the upregulation of various inflammatory cytokines after infection. Cytochrome P450, the main enzyme
in Metabolism of xenobiotics by cytochrome P450, is regulated by several inflammatory mediators and its
expression and activity is decreased with a host response to inflammation and infection [54].
These miRNAs and pathways are of interest because chronic inflammation is broadly associated with
tumorigenesis and cancer. Chronic inflammation has been shown to increase the risk of tumor formation, no-
tably demonstrated in the association between chronic inflammatory bowel disease and colon carcinogene-
sis. Inflammatory mediators and inflammation in the tumor microenvironment have many cancer-promoting
effects including promotion of malignant cells, angiogenesis, subversion of immune responses, metasta-
sis, induction of proneoplastic mutations, and altered response to hormones [55, 56, 57]. Proinflammatory
chemokines and cytokines have been found in the tumor microenvironment of many cancers and are typi-
cally induced by hypoxic conditions, which are characteristic of tumors [58].
In addition, several metabolic pathways are represented. Arginine and proline metabolism has been
known to exhibit changes in cancer [59], and the proline regulatory axis and proline metabolism both un-
dergo alterations that are posited to sustain and promote tumor cell growth [60, 61]. A plot of hsa-mir-146b
differentially regulating Arginine and proline metabolism is shown in Figure 6. Interestingly, two cancer
pathways (Pathways in Cancer and Basal Cell Carcinoma) contain the most predicted miRNA targets, in-
cluding cancer genes NRAS, CCDC6, CSF1R, SMAD4, ITGAV, and several others. However, it should
be noted that many miRNA–pathway pairs contain no predicted miRNA targets. Sequence matching using
TargetScan will fail to capture indirect interactions between miRNAs and pathway genes that may indeed be
captured using correlations. For instance, the IL-1R receptor family, which regulates hsa-mir-135b expres-
sion (see above), activates cytokines IL-6 and IL-8 which are present or interact with multiple inflammatory
pathways in Table 2, even though they are not predicted targets of hsa-mir-135b.
3.2 Prostate Cancer
hsa-mir-195 is flagged with many pathways in prostate cancer, shown in Table 3. hsa-mir-195 is frequently
reported as deleted or downregulated in tumors across multiple cancer types [62, 63, 64]. In prostate can-
cer hsa-mir-195 is under-expressed and has been shown to behave as a tumor suppressor by regulating
RPS6KB1 [65], BCOX1 [66], and FGF2 [67]. hsa-mir-195 itself is part of the hsa-mir-15 family cluster,
whose hsa-mir-15a has also been shown to behave as a tumor suppressor by regulating oncogenes BCL2,
CCND1 and WNT3 [68]. In advanced prostate tumors, hsa-mir-15a is downregulated or deleted and these
oncogene levels are markedly increased. Relatedly, the loss of the hsa-mir-15 family in prostate cancer has
been found to contribute to metastatic potential including bone lesions [69] (a marker of metastasis).
Many oncogenes are regulated by hsa-mir-195, including BCL2, CCND1, WNT3, AKT3, CDC42,
RAF1, and KRAS that lie on the pathways flagged with hsa-mir-195 in Table 3. These pathways include two
cancer pathways (Melanoma and Basal cell carcinoma), morphological pathways (Axon guidance and Focal
adhesion), and several signaling pathways whose genes are expected to be altered in tumors. Interestingly,
most miRNA–pathway pairs in Table 3, and particularly those with hsa-mir-195, exhibit much stronger cor-
relations in normal samples than in tumor samples. These trends may indicate general loss of function in
tumorigenesis, in concordance with documented under-expression of hsa-mir-195 in tumors.
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Table 3: Top prostate cancer pairs sorted by the most pronounced ∆ρ (p<10−5).
miRNA KEGG ID KEGG name ∆ρ ρT ρN size targets
hsa-mir-195 04360 Axon guidance -0.93 -0.19 0.75 128(129) 16(17)
hsa-mir-195 04510 Focal adhesion 0.88 0.18 -0.70 194(200) 30(31)
hsa-mir-195 05218 Melanoma 0.88 0.18 -0.70 63(71) 16(16)
hsa-mir-1307 05410 Hypertrophic cardiomyopathy (HCM) 0.86 0.38 -0.49 75(83) 0(0)
hsa-mir-195 05217 Basal cell carcinoma -0.85 -0.17 0.68 54(55) 10(10)
hsa-mir-1307 05414 Dilated cardiomyopathy -0.85 -0.39 0.46 81(90) 0(0)
hsa-mir-1307 04122 Sulfur relay system -0.85 -0.23 0.62 10(10) 0(0)
hsa-mir-200a 03022 Basal transcription factors -0.84 -0.17 0.68 35(36) 0(0)
hsa-mir-944 00982 Drug metabolism - cytochrome P450 -0.83 -0.52 0.32 55(73) 0(0)
hsa-mir-141 00592 alpha-Linolenic acid metabolism 0.83 0.42 -0.42 16(20) 0(0)
hsa-mir-195 04964 Proximal tubule bicarbonate reclamation 0.83 0.15 -0.67 22(23) 3(4)
hsa-mir-195 04912 GnRH signaling pathway 0.83 0.13 -0.70 92(101) 10(10)
hsa-mir-195 05414 Dilated cardiomyopathy 0.82 0.14 -0.69 81(90) 5(5)
hsa-mir-195 04664 Fc epsilon RI signaling pathway 0.82 0.14 -0.69 70(79) 10(10)
hsa-mir-195 05100 Bacterial invasion of epithelial cells 0.82 0.20 -0.62 69(70) 5(5)
Table 4: Top liver cancer pairs sorted by the most pronounced ∆ρ (p<10−5).
miRNA KEGG ID KEGG name ∆ρ ρT ρN size targets
hsa-mir-100 04115 p53 signaling pathway 0.85 0.38 -0.47 64(68) 0(0)
hsa-mir-3607 04320 Dorso-ventral axis formation 0.82 0.26 -0.56 20(24) 0(0)
hsa-mir-34a 04115 p53 signaling pathway 0.81 0.29 -0.53 64(68) 8(8)
hsa-mir-100 00360 Phenylalanine metabolism 0.81 0.53 -0.28 17(17) 0(0)
hsa-mir-210 03030 DNA replication -0.81 -0.45 0.36 36(36) 0(0)
hsa-mir-210 05219 Bladder cancer -0.81 -0.41 0.40 41(42) 0(0)
hsa-mir-210 05322 Systemic lupus erythematosus -0.81 -0.35 0.46 103(136) 0(0)
hsa-mir-210 04110 Cell cycle -0.81 -0.42 0.38 117(124) 0(0)
hsa-mir-148b 04614 Renin-angiotensin system 0.80 0.19 -0.61 14(17) 1(1)
hsa-mir-139 00053 Ascorbate and aldarate metabolism -0.80 -0.36 0.45 24(26) 0(0)
hsa-mir-34a 00620 Pyruvate metabolism 0.80 0.29 -0.51 37(40) 1(1)
hsa-mir-34a 00591 Linoleic acid metabolism 0.80 0.32 -0.47 23(30) 0(0)
hsa-mir-1247 00460 Cyanoamino acid metabolism -0.80 -0.46 0.34 7(7) 0(0)
hsa-mir-100 00983 Drug metabolism - other enzymes 0.79 0.56 -0.24 49(52) 0(0)
hsa-mir-139 00330 Arginine and proline metabolism 0.78 0.58 -0.20 51(54) 2(2)
3.3 Liver Cancer
In Table 4, flagged pairs for liver cancer are shown. miRNAs hsa-mir-100, hsa-mir-34a, and hsa-mir-210
are represented several times and are each known to be involved in hepatocellular carcinoma. hsa-mir-100
downregulation, concomitant with increased expression of its target PLK1, correlates with poor prognosis
and is an early event in hepatocarcinogenesis [70, 71]. Several studies have shown hsa-mir-34a to be a
tumor suppressor that activates apoptosis and cell senescence. In hepatocellular carcinoma, hsa-mir-34a
suppresses tumor invasion by modulating c-Met expression and is typically underexpressed [72, 73]. In
addition, hsa-mir-210 upregulation is increased in hypoxic conditions and contributes to metastatic potential
in hepatocellular carcinoma [74].
hsa-mir-100 and hsa-mir-34a are both found to differentially regulate the p53 signaling pathway in Ta-
ble 4. This is of interest because p53 is very commonly implicated in cancer, and in liver cancer, p53 loss
is associated with aggressive carcinomas and restoration of p53 has been shown to initiate tumor regres-
sion [75]. Notably, hsa-mir-34a and hsa-mir-34 family members are part of the p53 transcriptional network
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Table 5: Top lung cancer pairs sorted by the most pronounced ∆ρ (p<10−5).
miRNA KEGG ID KEGG name ∆ρ ρT ρN size targets
hsa-mir-141 04540 Gap junction -1.26 -0.52 0.74 84(90) 8(8)
hsa-mir-141 05146 Amoebiasis 1.19 0.54 -0.65 102(106) 5(5)
hsa-mir-203 04530 Tight junction 1.13 0.44 -0.69 121(132) 14(14)
hsa-mir-141 05100 Bacterial invasion of epithelial cells -1.13 -0.55 0.58 68(70) 5(5)
hsa-mir-141 04510 Focal adhesion 1.11 0.55 -0.56 195(200) 8(8)
hsa-mir-141 04916 Melanogenesis -1.11 -0.45 0.66 98(101) 5(5)
hsa-mir-141 04670 Leukocyte transendothelial migration 1.10 0.57 -0.53 109(116) 2(2)
hsa-mir-141 04974 Protein digestion and absorption -1.09 -0.53 0.56 70(81) 3(3)
hsa-mir-150 04973 Carbohydrate digestion and absorption 1.08 0.52 -0.56 35(44) 1(1)
hsa-mir-222 05146 Amoebiasis 1.07 0.43 -0.64 102(106) 1(1)
hsa-mir-141 05200 Pathways in cancer 1.06 0.53 -0.53 315(326) 25(25)
hsa-mir-150 04660 T cell receptor signaling pathway -1.05 -0.62 0.43 103(108) 4(4)
hsa-mir-200c 04540 Gap junction -1.05 -0.39 0.66 84(90) 13(13)
hsa-mir-141 04145 Phagosome 1.05 0.54 -0.51 142(153) 6(6)
hsa-mir-141 00260 Glycine, serine and threonine metabolism -1.04 -0.44 0.60 29(32) 0(0)
and are directly regulated by p53 [76, 77]. p53 induces the transcription of the hsa-mir-34 family, which
downregulates CDK4 and CDK6 to induce cell cycle arrest and BCL2 to promote apoptosis [78]. hsa-mir-
34a itself is predicted to directly regulate 8 targets on the p53 signaling pathway, including tumor-associated
genes CCND1, CCNE2, TP73, and CDK6. In addition, p53 induces the transcription of other miRNAs
(hsa-mir-145, hsa-mir-192/215, and hsa-mir-107) that modulate genes to induce cell cycle arrest, reduce
cell proliferation, and suppress angiogenesis [78].
3.4 Lung Cancer
Flagged pairs in lung cancer are shown in Table 5. hsa-mir-141 is represented frequently and is part of
a miRNA family containing five members arranged as two clusters, hsa-mir-200a/200b/429 and hsa-mir-
141/200c, that is thought to suppress the epithelial to mesenchymal transition (EMT). This is of interest
because the EMT is believed to be an important step in metastasis. The EMT is marked by decreased cell
adhesions including repression of E-cadherin and increased cell motility. This miRNA family has been
observed to play a role in the EMT of many cancer types, including bladder, breast, melanoma, prostate, and
lung cancer. In lung cancer, it has been shown to suppress the EMT with forced increased expression, while
EMT was observed in lung cancer cells with low expression of hsa-mir-200 [79]. In addition, hsa-mir-141
has been shown to be a prognostic indicator in lung cancer [80] and promotes proliferation by targeting
PHLPP1 and PHLPP2 [81].
It is notable that many of the pathways in Table 5 are morphological and dictate cellular processes
remodeled during the EMT. Gap junctions, Tight junctions, and Focal adhesions all undergo significant
changes to decrease cell-cell adhesions and promote invasion. In Table 5, miRNAs hsa-mir-141 and hsa-
mir-200c both differentially regulate Gap junctions (hsa-mir-141 vs. Gap junction PAS is shown in Figure 6).
Diminished Gap junctions or their elimination are seen as important indicators of tumorigenesis [82, 83]. In
addition, many cancer genes targeted by hsa-mir-141 and its family members are on the pathways in Table 5,
including SRC, PTEN, GRB2, CDK6, KRAS, DCC, and various protein kinases. These genes are reported
to play significant roles in multiple cancers in the literature.
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3.5 Pathway miRNA targets
It is reasonable to ask whether the associations detected between miRNAs and pathways are driven by an
abundance of targetted genes on those pathways. Tables 2–5 list the number of genes on the pathway that
are targetted by the associated miRNA. As noted above, several pathways do contain multiple targets of
a miRNA. However, we detect many more pathways that exhibit a differential association with a miRNA
despite the fact that the pathways are not known to contain miRNA targets. To address this question sys-
tematically, we tested whether an abundance of miRNA targets in a pathway was predictive of a strong
association in the analysis above. Briefly, we were unable to detect any relationship between the strength of
the differential miRNA–pathway association and the proportion of miRNA targets on the pathway. Further
details may be found in the Supplementary Information.
4 Discussion
We have described a new method for integrating miRNA and gene expression data to elucidate the role of
miRNAs in regulating functional pathways and identifying miRNA–pathway pairs whose co-regulation may
be disrupted in cancer.
Our approach improves upon other methods that have recently been proposed to study miRNA regu-
lation of pathways in cancer. Many of these approaches rely on miRNA target prediction coupled with
enrichment analyses. For instance, [84] identified prognostic miRNAs based on survival analysis and then
used functional network analysis to identify potential pathways regulated by those miRNAs using gene on-
tology terms, and [85] developed GSEA-FAME to infer miRNA activity from mRNA expression data using
enrichment and weighted miRNA–mRNA interaction methods. Both methods have been applied to TCGA
data in order to identify biomarkers and interpret miRNA function in cancer. However, functional enrich-
ment has been shown to contain bias [86], and commonly used in silico approaches tend to identify highly
related biological processes [40]. In addition, these methods typically ignore context dependent changes
in miRNA regulation; it is well known that miRNAs exhibit heterogeneous effects across cell, tissue, and
tumor types.
In contrast, our method does not rely on miRNA target prediction and functional enrichment, avoiding
those sources of bias. Rather, our approach is fully data driven, integrating sample specific miRNA and
mRNA expression data for identifying miRNA–pathway regulation. This takes into account any context de-
pendent behavior of miRNAs, since miRNA and mRNA expression are compared using the same biological
samples. By summarizing the gene expression behavior on the pathway with the PASinstead of performing
enrichment analysis, we capture the overall effect of the miRNA on the pathway, avoiding the bias intro-
duced by correlated genes [86]. The use of nonlinear dimension reduction to obtain the PASalso enables this
method to articulate complex coregulatory dynamics (such as that illustrated in Fig. 1). By comparing the
miRNA–pathway relationship in tumor tissue to that in adjacent normal tissue, the method is able to identify
regulatory relationships which are disrupted in disease. Other methods typically focus only on tumor tissue
and therefore cannot distinguish regulation uniquely affected in tumors.
Our pathway summary compresses high dimensional expression of all constitutive genes using samples
of both phenotypes in the same organ. Because it computes the summary collectively, in the context of
all other genes and samples, it does not rely on independent statistical associations with the phenotype
of interest. Importantly, this approach takes into account systemic effects and has the ability to articulate
nonlinear geometries, which may separate out phenotypes even if their boundaries are not convex. Class-
conditional correlations of the pathway summaries with miRNA expression between phenotypes can identify
aberrantly regulated miRNA–pathway relationships even in the absence of differential expression across
either the miRNA or pathway. This is in contrast to other approaches which rely on individual differential
expression of miRNAs or genes to detect systemic differences across phenotypes. The use of pathways,
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rather than individual genes, significantly reduces the search space of relevant processes while increasing
interpretability.
We integrate sample-specific miRNA and mRNA expression data from TCGA and compare tumor to
adjacent-normal tissue samples from breast, prostate, liver, and lung cancers. We find that within each cancer
type, more miRNA–pathway relationships are aberrantly regulated in tumors than expected by chance. This
supports the notion that complex diseases like cancer contain perturbations to entire systems rather than to a
few individual genes. Additionally, many of the flagged miRNAs and pathways have a biological basis for
disruption in cancer. We find specific relationships related to inflammatory processes, EMT modulation, and
tumor suppression (p53 signaling) that are highly perturbed in tumors. Comparison of results across cancer
types exhibited differences in the miRNA–pathway pairs detected, suggesting that the underlying molecular
mechanisms differ across tissues.
Because our method relies on statistical associations of expression data, it does not incorporate known
miRNA–gene target relationships a priori. To investigate whether our findings of significant miRNA–
pathway paris were driven by an abundance of miRNA targets on the pathway, we tested whether flagged
miRNA–pathway pairs were more likely to be enriched with predicted miRNA targets, and found poor
association in all cancer types (see Supplementary Information). We found no association between the sig-
nificance of the miRNA–pathway results and the number of miRNA target genes on the pathway, suggesting
that indirect coregulation of the miRNA and the pathway genes contributes to our results. Notably, the sig-
nificance of many miRNA–pathway pairs would be missed using methods that rely on miRNA target lists
to identify miRNA-regulated pathways. Other potential artifacts that could influence significance, such as
miRNA differential expression and pathway size, also showed little association with our findings (see Sup-
plementary Information), suggesting that these too are not driving our findings. Together, this supports the
view that the method is capable of detecting biologically significant miRNA–pathway relationships at the
systems level that either cause or emerge from a phenotype change, and which may be missed using other
approaches.
Finally, while we apply our algorithm to miRNA and gene expression data in cancer, we note that
it can be generalized to other experimental modalities and diseases, provided sufficient data for cases and
controls. Future applications could include other regulatory mechanisms such as transcription factors, epige-
netic modifications, or small molecule inhibitors. In addition, other complex diseases could be investigated
that are thought to undergo significant perturbations at the systems level. Identifying altered associations
at the systems level helps narrow down the search space for responsible mechanisms that contribute to
tumorigenesis.
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7 Supplementary Information
7.1 Data and Processing
Preprocessing We downloaded mRNA expression data sets (sequenced on an IlluminaHiSeq RNASeqV2
platform, TCGA data level 3) and miRNA expression data sets (sequenced on an IlluminaHiSeq miRNASeq
platform, TCGA data level 3) for primary tumor samples (tissue label “01”) and adjacent-normal sam-
ples (tissue label “11”) for breast (BRCA), lung (LUSC), liver (LIHC), and prostate (PRAD) cancers from
TCGA. We normalized mRNA libraries such that the sum of all transcripts in each library was one, making
them comparable between samples. Afterwards, we filtered out genes which had very low median expres-
sion across all samples (≤ 10−9 in the “scaled estimate” column), since several genes had no discernible
expression across most samples in the set. The remaining mRNA data were then multiplied by 106 to obtain
transcripts per million (TPM) as described in [1] and then log2 transformed, including the addition of a
small offset (10−10) for the log2 transformation.
miRNA expression data were downloaded from the same TCGA samples and similarly preprocessed,
in which miRNA libraries were normalized such that the sum of all transcripts in each library was one. After-
wards, miRNAs with very low median expression across all samples (≤ 0.001 in the “reads per million miRNA mapped”
column) were filtered out.
Data In breast cancer, 1203 samples (1092 tumor, 111 adjacent-normal) were used to compute the PAS,
of which 758 (671 tumor, 87 adjacent-normal) samples were used for class-conditional correlations with
444 miRNAs. In prostate cancer, PAScomputation used 538 samples (486 tumor, 52 adjacent-normal),
of which 534 (482 tumor, 52 adjacent-normal) samples were used for class-conditional correlations with
416 miRNAs. Liver cancer PAScomputation used 401 samples (351 tumor, 50 adjacent-normal), of which
397 samples (347 tumor, 50 adjacent-normal) were used for correlations with 397 miRNAs. Finally, lung
cancer used 553 samples (502 tumor, 51 adjacent-normal) for PAS, of which 380 samples (342 tumor, 38
adjacent-normal) were used for correlations with 380 miRNAs.
Isomap parameter choice Isomap applies MDS on a distance matrix that approximates geodesic dis-
tances, constructed by a k-nearest neighbors search and computing shortest paths. It is a well known result
that classical MDS (using euclidean distance) and PCA produce identical spectra, with extra zero eigen-
values accounting for the difference in input dimensions. This is because the rank of the data is the same.
Mathematically, this is demonstrated as follows: if X is an input matrix, spanning s samples by g genes
(mean centered), the spectra of XTX and XXT will be identical, with extra s− g zero eigenvalues. There-
fore, in the high-k limit, Isomap and PCA will produce identical spectra because the distance matrix is
euclidean and no geodesic distances will be imputed.
7.2 Systems Effects
Because our method relies on statistical associations, it does not necessarily select miRNAs and pathways
having known biological relationships. We therefore tested all miRNA-pathway pairs to determine whether
altered associations were more likely to be enriched with predicted miRNA targets. Each miRNA’s predicted
mRNA targets were taken from TargetScan and significance was assessed using a hypergeometric test. Scat-
terplots of enrichment vs. altered association are shown in Figure 8. Target enrichment did not correlate well
with ∆ρ significance in each cancer type (all ρ<0.1).
It should be noted that other potential explanatory mechanisms did not explain flagged miRNA–pathway
relationships. We found poor association between miRNA differential expression (using a Student’s t-test)
and the number of flagged pathways with each miRNA in each organ type, shown in Figure 9. Additionally,
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Figure 8: Scatterplots of enrichment significance (− log10 pE) vs. ∆ρ significance (− log10 pdisr) for all
miRNA × pathway pairs within each cancer type. Rank correlations are displayed within each figure.
we investigated whether larger pathways are more likely to be flagged since they invariably contain more
miRNA targets. We also found poor association between pathway size and significance, shown in Figure 10.
These results suggest that differential regulations are likely driven by systems effects, rather than by specific
individual interactions or scale effects.
7.3 Cross-cancer comparison
We illustrate the comparison of all miRNA–pathway pairs across different organs using a scatterplot matrix
of their ∆ρ significance, shown in Figure 11. Cancer types exhibit poor concordance with one another, since
the Spearman’s rank correlation of their miRNA–pathway pairs’ p-values are fairly low (shown in the upper
right panels). This discordance may be visualized by the lower heat map panels of p-value density. High
concordance would be evidenced by high density (darker colors) along the diagonal, which is not observed.
Instead, high density is located in regions with low significance in at least one or both cancers being com-
pared. Thus, each cancer type appears to contain a unique profile of miRNA–pathway relationships which
are significantly changed in tumor tissue. This may be attributable to the fact that the PAS is computed
conditional on cancer type, which could distort cross-cancer comparisons.
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Figure 9: Marginal miRNA differential expression, as calculated by Student’s t-test between tumor and
adjacent-normal tissue, does not determine the number of pathways differentially regulated by a miRNA
(p<0.01).
It is notable that within each cancer type, there are more pairs with significant ∆ρ than expected by
chance alone. The diagonal panels in Figure 11 illustrate the within-cancer − log10 p distributions, in which
breast cancer has by far the largest proportion of significant pairs out of all pairs investigated, followed by
lung, prostate, and finally liver cancer. In general, a multitude of miRNA regulatory effects at the pathway
level appear to be disrupted, in agreement with the literature implicating broad miRNA disregulation in
tumors.
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Figure 10: Pathway size does not generally influence pathway significance. The size of the pathway does
not correlate appreciably with the number of miRNAs differentially regulating (p<0.01) that pathway. Lung
cancer does appear to have a size-dependence unlike the other cancers.
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Figure 11: Scatterplot matrix showing the significance of ∆ρ for all miRNA–pathway pairs across can-
cer types. Lower panels display the scatterplot density heat map for − log10 p between cancer types, in
which darker colors denote higher density. Diagonal panels display− log10 p histograms within each cancer
type, overlaid with − log10 p null distribution drawn by the red curve. Upper panels display the Spearman
correlation coefficient of p-values between cancer types across all pairs.
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